JPRN-UMIN000046410Completed未知
Prospective feasibility study on the efficacy and safety of the novel spiral dilator for EUS-guided drainage - Prospective feasibility study on the efficacy and safety of the novel spiral dilator for EUS-guided drainage
Sendai City Medical Center0 sites10 target enrollmentStarted: December 18, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
The technical success rate and the success rate of dilation using a Tornus ES were both 100%. The mean procedure time was 27 minutes. No adverse events related to the procedure occurred in all cases.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •bleeding tendency poor general condition massive ascites around the pancture site pregnancy
Investigators
Similar Trials
Completed
Not Applicable
A study to determine the effectiveness of a tailor-made prevention programme (as part of Minimally Invasive Dentistry approach) for individuals with dental phobia (high levels of dental anxiety) compared to usual careTreatment of dental caries and periodontal disease in patients with dental phobiaOral HealthDental caries, periodontal diseaseISRCTN15294714King's College London44
Suspended
Not Applicable
ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating GliomaGliomaNCT03322813InSightec15
Completed
Phase 2
A phase II study of percutaneous trans-esophageal gastric tubing for malignant gastrointestinal obstruction (JIVROSG-0205)Malignant gastrointestinal obstructionJPRN-C000000042Japan Interventional Radiology in Oncology Study Group (JIVROSG)33
Active, not recruiting
Not Applicable
ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's DiseaseParkinson's DiseaseNCT02347254InSightec6
Not yet recruiting
Not Applicable
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL: FL grade 3b and DLBCNL-OMON24909Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl60